Our new prognosis gene signature for lung adenocarcinoma meets that need with risk‐stratification ability on mutation status of EGFR and TP53, levels of immune checkpoint PD‐L1 expression, and with and without adjuvant chemotherapy. This evidence concerns the gene EGFR and lung adenocarcinoma.